CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
REVENUES:
Total revenues	$ 391,706	$ 334,148	$ 1,137,998	$ 955,341
OPERATING EXPENSES:
Cost of sales	78,893	59,480	240,245	165,791
Research and development	161,408	154,103	520,938	442,145
Selling, general and administrative	148,566	130,532	440,182	394,056
Intangible asset amortization and contingent consideration	18,580	3,760	42,009	26,096
Gain on sale of intangible assets	0	0	20,000	0
Total operating expenses	407,447	347,875	1,223,374	1,028,088
LOSS FROM OPERATIONS	(15,741)	(13,727)	(85,376)	(72,747)
Equity in the loss of BioMarin/Genzyme LLC	(468)	(253)	(507)	(996)
Interest income	6,338	3,976	17,141	10,031
Interest expense	(12,131)	(10,884)	(35,918)	(31,043)
Other income, net	2,589	267	5,266	4,282
LOSS BEFORE INCOME TAXES	(19,413)	(20,621)	(99,394)	(90,473)
Benefit from income taxes	(6,793)	(8,094)	(25,833)	(24,823)
NET LOSS	$ (12,620)	$ (12,527)	$ (73,561)	$ (65,650)
NET LOSS PER SHARE, BASIC AND DILUTED	$ (0.07)	$ (0.07)	$ (0.42)	$ (0.38)
Weighted average common shares outstanding, basic and diluted	177,481	175,103	176,767	174,071
COMPREHENSIVE LOSS	$ (13,651)	$ (19,303)	$ (52,174)	$ (99,900)
Net Product Revenues
REVENUES:
Total revenues	386,320	298,752	1,123,205	916,868
Royalty and Other Revenues
REVENUES:
Total revenues	$ 5,386	$ 35,396	$ 14,793	$ 38,473